Postexposure Prophylaxis in Children and Adolescents for Nonoccupational Exposure to Human Immunodeficiency Virus
- 1 June 2003
- journal article
- review article
- Published by American Academy of Pediatrics (AAP) in PEDIATRICS
- Vol. 111 (6), 1475-1489
- https://doi.org/10.1542/peds.111.6.1475
Abstract
Exposure to human immunodeficiency virus (HIV) can occur in a number of situations unique to, or more common among, children and adolescents. Guidelines for postexposure prophylaxis (PEP) for occupational and nonoccupational (eg, sexual, needle-sharing) exposures to HIV have been published by the US Public Health Service, but they do not directly address nonoccupational HIV exposures unique to children (such as accidental exposure to human milk from a woman infected with HIV or a puncture wound from a discarded needle on a playground), and they do not provide antiretroviral drug information relevant to PEP in children. This clinical report reviews issues of potential exposure of children and adolescents to HIV and gives recommendations for PEP in those situations. The risk of HIV transmission from nonoccupational, nonperinatal exposure is generally low. Transmission risk is modified by factors related to the source and extent of exposure. Determination of the HIV infection status of the exposure source may not be possible, and data on transmission risk by exposure type may not exist. Except in the setting of perinatal transmission, no studies have demonstrated the safety and efficacy of postexposure use of antiretroviral drugs for the prevention of HIV transmission in nonoccupational settings. Antiretroviral therapy used for PEP is associated with significant toxicity. The decision to initiate prophylaxis needs to be made in consultation with the patient, the family, and a clinician with experience in treatment of persons with HIV infection. If instituted, therapy should be started as soon as possible after an exposure—no later than 72 hours—and continued for 28 days. Many clinicians would use 3 drugs for PEP regimens, although 2 drugs may be considered in certain circumstances. Instruction for avoiding secondary transmission should be given. Careful follow-up is needed for psychologic support, encouragement of medication adherence, toxicity monitoring, and serial HIV antibody testing.Keywords
This publication has 94 references indexed in Scilit:
- Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trialThe Lancet, 2002
- Feasibility of Postexposure Prophylaxis (PEP) against Human Immunodeficiency Virus Infection after Sexual or Injection Drug Use Exposure: The San Francisco PEP StudyThe Journal of Infectious Diseases, 2001
- Is offering post-exposure prevention for sexual exposures to HIV related to sexual risk behavior in gay men?AIDS, 2000
- Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trialThe Lancet, 1999
- Trends in Human Immunodeficiency Virus (HIV) Counseling, Testing, and Antiretroviral Treatment of HIV‐Infected Women and Perinatal Transmission in North CarolinaThe Journal of Infectious Diseases, 1999
- A Case–Control Study of HIV Seroconversion in Health Care Workers after Percutaneous ExposureThe New England Journal of Medicine, 1997
- Epidemiology of HIV Infection in Women and NewbornsClinical Obstetrics and Gynecology, 1996
- Cell-Mediated Immune Response to Human Immunodeficiency Virus (HIV) Type 1 in Seronegative Homosexual Men with Recent Sexual Exposure to HIV-1The Journal of Infectious Diseases, 1992
- Failure of Zidovudine Prophylaxis after Accidental Exposure to HIV-1The New England Journal of Medicine, 1990
- Infrequency of Isolation of HTLV-III Virus from Saliva in AIDSThe New England Journal of Medicine, 1985